Savara (NASDAQ:SVRA) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

by · The Cerbat Gem

Savara (NASDAQ:SVRA – Get Free Report) had its price objective boosted by Wells Fargo & Company from $7.00 to $9.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective would suggest a potential upside of 48.39% from the stock’s current price.

A number of other analysts have also issued reports on SVRA. Wall Street Zen upgraded Savara from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Oppenheimer boosted their target price on shares of Savara from $8.00 to $9.00 and gave the stock an “outperform” rating in a report on Friday, November 14th. Citigroup reiterated an “outperform” rating on shares of Savara in a research report on Thursday, October 23rd. Citizens Jmp dropped their target price on shares of Savara from $11.00 to $10.00 and set a “market outperform” rating on the stock in a research report on Thursday, November 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Savara has an average rating of “Moderate Buy” and a consensus price target of $8.57.

View Our Latest Stock Report on Savara

Savara Stock Down 0.7%

Shares of NASDAQ SVRA traded down $0.05 during mid-day trading on Thursday, reaching $6.07. The company had a trading volume of 314,500 shares, compared to its average volume of 1,553,978. The stock has a market cap of $1.23 billion, a P/E ratio of -11.39 and a beta of 0.23. The company has a current ratio of 7.65, a quick ratio of 7.65 and a debt-to-equity ratio of 0.32. Savara has a 52-week low of $1.89 and a 52-week high of $7.01. The firm has a 50 day simple moving average of $4.83 and a two-hundred day simple moving average of $3.53.

Savara (NASDAQ:SVRA – Get Free Report) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). Sell-side analysts predict that Savara will post -0.45 earnings per share for the current year.

Hedge Funds Weigh In On Savara

Several hedge funds and other institutional investors have recently modified their holdings of the stock. CIBC Bancorp USA Inc. acquired a new position in shares of Savara during the 3rd quarter worth about $44,000. Woodline Partners LP lifted its holdings in Savara by 52.2% during the 3rd quarter. Woodline Partners LP now owns 237,221 shares of the company’s stock worth $847,000 after buying an additional 81,361 shares during the last quarter. VR Adviser LLC increased its holdings in shares of Savara by 42.7% in the 3rd quarter. VR Adviser LLC now owns 12,681,043 shares of the company’s stock valued at $45,271,000 after acquiring an additional 3,796,780 shares during the period. Nantahala Capital Management LLC increased its stake in shares of Savara by 5.4% during the third quarter. Nantahala Capital Management LLC now owns 8,775,375 shares of the company’s stock worth $31,328,000 after acquiring an additional 450,000 shares during the period. Finally, Millennium Management LLC acquired a new stake in shares of Savara in the third quarter valued at about $3,014,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

Savara Company Profile

(Get Free Report)

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Featured Articles